Stock ownership · SEC 13F · Q2 2025

Y-MABS THERAPEUTICS INC

A breakdown of Y-MABS THERAPEUTICS INC's institutional base (CUSIP 984241109): the holders, the concentration among them, and what changed last quarter.

$96K
Reported value
2
Institutions
100%
Top-5 share

The verdict

$96K of Y-MABS THERAPEUTICS INC is reported by 2 institutions as of Q2 2025; ownership is held overwhelmingly by a small core of institutions.

2
institutions hold it
$96K
reported 13F value
100%
held by top 5

Based on long positions reported to the SEC as of Q2 2025; 13F omits shorts, options and non-US holdings.

How to read this page

This page summarizes how large institutional investment managers report holding this security in their quarterly SEC Form 13F-HR filings. A 13F filing is a mandatory disclosure that any manager with at least $100 million in qualifying US-listed equity assets must submit to the Securities and Exchange Commission within 45 days of the end of each calendar quarter. The figures here therefore describe long equity positions as of a specific reporting quarter, not live market quotes, and not a manager's complete book. 13F disclosures deliberately exclude short positions, cash, most derivatives, non-US listings, and small holdings, so the institutional ownership shown is a floor rather than a full picture. "Holders" counts the distinct managers reporting a position; "reported value" sums the market value those managers disclosed; and "top-5 concentration" measures how much of that reported value sits with the five largest holders. Use these numbers to understand institutional interest and how it shifts quarter over quarter, never as a recommendation to buy or sell. Every figure is rendered directly from the underlying filings and can be verified against the original documents on SEC EDGAR. This page is provided for informational purposes only and is not financial advice, consult a licensed financial advisor before making investment decisions.

Reported value

$96K

Institutional 13F value

Institutions

2

Reporting holders

Top-5 concentration

100%

Held by 5 largest

New buyers

2

Opened Q2 2025

Concentrated ownership

Top-5 holder concentration

0%100%100%
Top-5 holder concentration
Share of reported value held by the 5 largest institutions · Q2 2025

Institutional ownership over time

The number of institutions reporting a Y-MABS THERAPEUTICS INC position has risen from 1 to 2 over the last 5 quarters of 13F filings.

0.511.522.5 Q1'24Q3'24Q4'24Q1'25Q2'25 2
Distinct 13F filers holding Y-MABS THERAPEUTICS INC, by quarter

Top Institutional Holders

# Institution Shares Value Share of reported
1 Squarepoint Ops LLC 12,233 $55K 57.4%
2 China Universal Asset Management Co., Ltd. 9,097 $41K 42.6%

Latest Quarter Activity · Q2 2025

Complete exits (2)

What the data says about Y-MABS THERAPEUTICS INC

A handful of institutions account for most of the reported institutional float here.

  • See how Y-MABS THERAPEUTICS INC's holder count and reported value have shifted quarter over quarter. Biggest movers
  • Check where this stock ranks among the most widely held names before treating one position as a signal. Most-held stocks
  • Review the gaps in 13F reporting before drawing conclusions from it. 13F limitations

Informational only, not investment advice. 13F is a 45-day-lagged snapshot of long US-equity positions; holdings may have changed.

Frequently Asked Questions

How many institutions hold Y-MABS THERAPEUTICS INC?
Y-MABS THERAPEUTICS INC is held by 2 institutional investors per the latest SEC Form 13F filings as of Q2 2025.
What is the total institutional value of Y-MABS THERAPEUTICS INC?
Institutions report $96K of Y-MABS THERAPEUTICS INC as of Q2 2025.
How concentrated is ownership of Y-MABS THERAPEUTICS INC?
The top five institutional holders account for 100% of the reported institutional value in Y-MABS THERAPEUTICS INC, making ownership held overwhelmingly by a small core of institutions.
Who is the largest institutional holder of Y-MABS THERAPEUTICS INC?
Squarepoint Ops LLC is the largest reported holder of Y-MABS THERAPEUTICS INC with $55K across 12,233 shares as of Q2 2025.
Where does this Y-MABS THERAPEUTICS INC data come from?
Every figure is rendered live from SEC Form 13F-HR filings in the EDGAR system. 13F is a mandatory quarterly disclosure of long US-listed equity positions, filed within 45 days of each quarter-end.

Source: U.S. Securities and Exchange Commission (SEC) - EDGAR Form 13F-HR institutional holdings filings · Q2 2025 13F-HR discloses long US-listed equity positions of managers with $100M+ qualifying assets, filed within 45 days of period end. Short positions and most derivatives are not disclosed.